https://www.selleckchem.com/pr....oducts/3-methyladeni
and to serve as novel therapeutic targets. After stereotactic body radiation therapy (SBRT) for medically inoperable stage I non-small-cell lung cancer (NSCLC), more patients die of comorbidities, particularly severe pulmonary insufficiency, than of tumor progression. The aim of this study was to evaluate correlation between lung biologically effective dose (BED) with an α/β ratio of 3 Gy (BED ) and overall survival (OS) for these patients. From 2012 to 2017, we have developed a prospectively updated institutional database for a
Like
Comment
Share
